RecruitingPhase IIFemale onlyEN originalOvarian cancer

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that has come back (recurrent). Anti-CD40 CDX-1140 works by stimulating certain immune cells within the tumor and, when combined with other immunotherapy treatments, may increase antitumor antibody production. Immunotherapy with monoclonal antibodies, such as pembrolizumab and bevacizumab, may help the body's immune system, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab and bevacizumab with anti-CD40 CDX-1140 may decrease symptoms, prolong survival, and improve quality of life in patients with ovarian cancer.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek co najmniej 18 lat
  • Nawracający rak jajnika, jajowodu lub otrzewnej (tego rodzaju nowotwory już wróciły po wcześniejszym leczeniu)
  • Maksymalnie 4 poprzednie linie leczenia
  • Znany status genu BRCA
  • Spodziewana długość życia większa niż 6 miesięcy
  • Dobrze funkcjonujący układ immunologiczny i organy wewnętrzne (testy krwi i nerek w normie)
  • Możliwość zmierzenia guzów na badaniach obrazowych
  • Wyleczenie się z skutków ubocznych poprzednich terapii

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
August 14, 2026
Sex
Female only

Therapies / drugs in trial

Locations (2)

Roswell Park Cancer Institute

Buffalo, United States

M D Anderson Cancer Center

Houston, United States

Trial contact

Emese Zsiros

PRINCIPAL_INVESTIGATOR

Amir A. Jazaeri

PRINCIPAL_INVESTIGATOR

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/15/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.